Last reviewed · How we verify
Bromosulphalein — Competitive Intelligence Brief
unknown
sulfobromophthalein
Hematopoietic prostaglandin D synthase
Hematology
Live · refreshed every 30 min
Target snapshot
Bromosulphalein (sulfobromophthalein). Bromosulphalein works by binding to and inhibiting the enzyme hematopoietic prostaglandin D synthase.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bromosulphalein TARGET | sulfobromophthalein | unknown | sulfobromophthalein | Hematopoietic prostaglandin D synthase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (sulfobromophthalein class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bromosulphalein CI watch — RSS
- Bromosulphalein CI watch — Atom
- Bromosulphalein CI watch — JSON
- Bromosulphalein alone — RSS
- Whole sulfobromophthalein class — RSS
Cite this brief
Drug Landscape (2026). Bromosulphalein — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfobromophthalein. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing